Clinical Trials Browser

Carcinoma, Transitional Cell × Albumin-Bound Paclitaxel × Clear all

Carcinoma, Transitional Cell

NCT02887248 2023-12-05

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

Phase 2 Terminated

3 enrolled 9 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01478685 2019-11-12

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Phase 1 Completed

169 enrolled

GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Tumor Virus Infections, Carcinoma, Pancreatic Ductal

NCT00683059 2016-10-17

Single Agent Abraxane as Second Line Therapy in Bladder Cancer

Phase 2 Completed

48 enrolled

Genitourinary

Carcinoma, Transitional Cell

Clinical Trials

ABLE

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Single Agent Abraxane as Second Line Therapy in Bladder Cancer